Myeloproliferative disease and myelodysplastic syndrome induced by transplantation of bone marrow cells expressing mutant p53

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Leukemia

• Publication date

  1997-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.leu.2400782PMID 9324283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Retroviral transduction of hematopoietic progenitor cells with mutant p53 promotes survival and proliferation, modifies differentiation potential and inhibits apoptosis.

  1996cited by this paper
• Transformation of FDC-P1 cells to IL-3 independence by a recombinant murine retrovirus containing v-erb-B.

  1995cited by this paper
• A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice

  1995cited by this paper
• The aberrant p53 protein (review).

  1995cited by this paper
• The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma.

  1995cited by this paper
• Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes.

  1995cited by this paper
• An internal deletion enhances the transcriptional activity of a recombinant retrovirus in hematopoietic cells in vivo

  1994cited by this paper
• Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation.

  1994cited by this paper
• p53 in hematologic malignancies.

  1994cited by this paper
• Retroviral vector design for long-term expression in murine hematopoietic cells in vivo.

  1994cited by this paper
• The tumor suppressor genes.

  1993cited by this paper
• Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.

  1993cited by this paper
• Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression

  1993cited by this paper
• Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.

  1993cited by this paper
• Oncogenic forms of p53 inhibit p53-regulated gene expression.

  1992cited by this paper
• Both myeloproliferative disease and leukemia are induced by transplantation of bone marrow cells expressing v-myc.

  1992cited by this paper
• Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

  1992cited by this paper
• Definition of a consensus binding site for p53

  1992cited by this paper
• Wild-type p53 activates transcription in vitro

  1992cited by this paper
• Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.

  1992cited by this paper
• Mammalian p53 can function as a transcription factor in yeast.

  1992cited by this paper
• Constitutive expression of p53 protein in enriched normal human marrow blast cell populations.

  1992cited by this paper
• p53 transgenic mice: accelerated erythroleukemia induction by Friend virus.

  1991cited by this paper
• Leukemia and the disruption of normal hematopoiesis.

  1991cited by this paper
• Mutant p53 proteins bind DNA abnormally in vitro.

  1991cited by this paper
• Mutations in the p53 gene in myelodysplastic syndromes.

  1991cited by this paper
• Tumor suppressor p53: analysis of wild-type and mutant p53 complexes

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

  1991cited by this paper
• Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

  1991cited by this paper
• Tumor suppressor genes.

  1991cited by this paper
• Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

  1990cited by this paper
• Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation

  1989cited by this paper
• The p53 proto-oncogene can act as a suppressor of transformation.

  1989cited by this paper
• High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

  1989cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Increased expression of p53 protein in human leukemia cells.

  1986cited by this paper
• Expression of p53 in human leukemia and lymphoma.

  1986cited by this paper
• Expression of the p53 oncogene in acute myeloblastic leukemia

  1986cited by this paper

• Mutant p53 in cancer therapy—the barrier or the path

  2018cites this paper
• Pathogenesis and mutations of myeloproliferative neoplasms: an overview.

  2015cites this paper
• MİYELOPROLİFERATİF NEOPLAZİLERDE MOLEKÜLER OLAYLARIN ÖNEMİ THE IMPACT OF MOLECULAR EVENTS ON MYELOPROLIFERATIVE NEOPLASMS İpek Yönal HİNDİLERDEN*, Fehmi HİNDİLERDEN**, Deniz SARGIN***

  2015cites this paper
• Cancer gene suppression strategies: issues and potential.

  2004cites this paper
• The β-Galactosidase Gene as a Marker for Hematopoietic Reconstitution: Individual Cell Analysis in a Murine Bone Marrow Transplantation Model

  2000cites this paper
• Introduction: overview of chronic myeloproliferative disorders.

  1999cites this paper
• Molecular genetic features of myelodysplastic syndromes (MDS)

  1999cites this paper